Catherine Dunn

Apple’s already the pack leader when it comes to wearables but its eager to grow that lead.

Cigna Group investors will be looking for more detail on the growth of its specialty pharmacy business under new CEO Brian Evanko.

Barclays upgraded Humana stock to Overweight from Neutral and raised its price target to $515 from $407.

Drug companies had incentives to participate in the deals to stave off the threat of U.S. tariffs on their products.

As employers brace for a fresh round of rising healthcare costs that outpace inflation, the stakes are getting higher for companies to contain spending on treatments such as popular GLP-1 medications for weight loss.

In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.

The nine drug companies committed to collectively invest at least $19.6 billion in U.S. manufacturing in the near term.

Hims & Hers Health is shifting its core weight-loss business from compounded GLP-1 drug sales to branded versions of the medications.

Oscar Health’s medical loss ratio—the percentage of premium revenue spent on medical claims—fell to 79.2% from 91.1%,

CVS Health posts better-than-expected second-quarter earnings and raises its full-year outlook.

Cigna Group beats quarterly earnings estimates and nudges its full-year outlook higher.

Teva can look beyond President Donald Trump’s threat of a tariff on generic drugs. Teva has a pipeline of branded drugs that has caught Wall Street’s attention.

Humana has surged this year on improving confidence in Medicare Advantage insurers.

The company gets most of its revenue from branded GLP-1s and other products. Most analysts see the stock fully valued.

President Donald Trump’s threat of 100% tariffs on generic drugs would seem to be a problem for Teva Pharmaceutical. It might not be.

Molina healthcare has seen its stock edge down in recent days amid concerns about Medicaid cost pressures.

Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.

The healthcare giant posts better-than-expected second-quarter earnings and hikes its full-year guidance.

Elevance Health’s earnings beat wasn’t enough to outweigh high Medicaid spending.

Shares of CVS Health closed slightly higher Tuesday, about a quarter of a percentage point.